시장보고서

상품코드

1555474

인플루엔자 치료제 시장 : 부문별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Influenza Medications Market, By Drug Type, By Influenza Type, By Age Group, By Route of Administration, By Distribution Channel and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 08월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 399 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

2023년 인플루엔자 치료제(Influenza Medications) 시장 규모는 9억 3,243만 달러였으며, 2024년부터 2032년까지 CAGR 7.2%로 추이하며 확대 될 것으로 예상

인플루엔자 치료제 시장-시장 역학

인플루엔자 이환율 증가가 시장 성장을 이끌 것으로 예측

독감은 계절적으로 반복적으로 발생하는 질병으로, 세계 각지의 여러 지역에서 매년 유행합니다. 인플루엔자 계절에 발생률이 높아지면 의약품에 의한 개입에 대한 수요가 증가합니다. 또한 산발적 인플루엔자의 유행과 유행은 인플루엔자의 발생률을 크게 증가시킬 수 있으므로 항바이러스 요법과 예방 전략의 필요성이 급증합니다. 미국 질병예방관리센터(CDC)는 이번 시즌 인플루엔자에 의한 환자 수는 3,500만 명 이상, 입원자 수는 40만 명, 사망자 수는 2만 5,000명으로 추정하고 있습니다. 또한, 항바이러스제와 종합적인 치료법의 개발에 있어서 진보는 시장에 큰 성장 기회를 가져오고 있습니다. 그럼에도 불구하고, 신약과 관련된 높은 비용이 시장 확대의 과제가 될 가능성도 있습니다.

인플루엔자 치료제 시장-주요 인사이트

우리 리서치 애널리스트 분석에 따르면 세계 시장은 예측 기간(2024-2032년) 동안 약 7.2%의 CAGR로 매년 성장할 것으로 추정됩니다.

약제 유형별로 항바이러스제물이 2023년에 가장 큰 시장 점유율을 나타냈습니다.

인플루엔자의 유형별로는 2023년에는 인플루엔자 A형이 주요 유형이었습니다.

연령층별로는 2023년에는 성인이 주요 유형이었습니다.

투여 경로의별 세분화에 기초하여, 2023년에는 경구제가 주요 유형이었습니다.

유통 채널별로는 2023년에는 병원 약국이 주요 유형이 되었습니다.

지역별로는 북미가 2023년 가장 많은 수익을 창출했습니다.

인플루엔자 치료제 시장-세분화 분석 :

세계의 인플루엔자 치료제 시장은 약제 유형, 독감 유형, 연령대, 투여 경로, 유통 채널, 지역에 따라 세분화됩니다.

시장은 약제 유형에 따라 세 가지로 분류됩니다 : 항바이러스제, 항히스타민제, 진통 및 해열제입니다. 항바이러스제는 시장에서 압도적인 지위를 차지합니다. 이러한 약제은 독감 증상의 강도와 길이를 완화하기 위해 처방되며 경우에 따라 합병증을 피할 수 있습니다.

시장은 인플루엔자 유형에 따라 두 가지 부문으로 분류됩니다 : 인플루엔자 A형과 인플루엔자 B형입니다. A형 인플루엔자는 매년의 인플루엔자 유행의 방아쇠가 되는 역할을 담당하고 있어, 그 급속한 변이 능력에 의해 팬데믹을 일으키는 능력을 가지고 있는 것이 인식되고 있습니다.

시장은 연령대별로 세 가지 부문으로 분류됩니다 : 성인, 소아, 노년. 성인은 시장을 독점하고 있습니다. 성인은 계절성 인플루엔자에 자주 앓고 있으며, 그 중증도는 연령, 기초 질환, 백신 접종력 등 요인에 영향을 받기 때문에 성인에 초점을 맞춘 인플루엔자 치료제 시장은 매우 중요한 부문입니다.

시장은 투여 경로에 따라 다음 범주로 분류됩니다 : 경구, 흡입, 정맥 내. 시장에서는 경구제가 압도적인 지위를 차지하고 있습니다. 경구 항바이러스제는 특히 경증에서 중등증 치료에서 인플루엔자 대책의 주요 옵션이 되는 경우가 많습니다.

시장은 유통 채널에 의해 세 가지 범주로 분류됩니다 : 병원 약국, 소매 약국, 온라인 약국. 병원 약국이 시장을 독점하고 있습니다. 병원에서는 고령자, 지병이 있는 사람, 면역력이 저하된 사람 등 중증화할 위험이 높은 환자를 치료하기 위해 효율적인 항바이러스 치료가 필요합니다.

인플루엔자 치료제 시장-지리적 통찰

이 시장은 북미, 남미, 유럽, 아시아 태평양, 중동 및 아프리카를 포함한 광범위한 지역에 걸쳐 있습니다. 이 지역은 사업 활동에 기여하는 국가에 따라 추가로 분류됩니다. 북미는 첨단 약제 요법의 채택과 건강 관리 지출 증가로 시장을 선도하고 있습니다. 북미, 특히 미국의 규제 체제는 신형 인플루엔자 치료의 신속한 승인과 시행을 촉진하고 있습니다. 여기에는 다른 지역에서는 아직 사용할 수 없는 혁신적인 치료법에 대한 액세스도 포함됩니다. 2022년에는 신약이라는 총 37개의 신약이 미국에서 처음 승인되었습니다. 게다가 미국 국립위생통계센터의 보고에 따르면 이미 승인된 약제은 새로운 적응증과 환자층을 포함한 새로운 용도로 승인되었습니다. 유럽은 인지도 향상과 조기 진단 증가로 시장 확대의 2위를 차지하고 있습니다.

인플루엔자 치료제 시장-경쟁 구도 :

인플루엔자 치료제 시장은 특히 항바이러스제 분야에서 더 큰 점유율을 확보하려는 다수의 제약 회사에 의해 특징지어지는 높은 수준의 경쟁을 나타냅니다. 이 경쟁의 중요한 초점은 독특한 작용 메커니즘을 채택한 새로운 항바이러스제물의 혁신에 있습니다. 내성을 극복하고 효능과 편의성을 향상시킬 수 있는 고급 인플루엔자 치료제를 처방하기 위한 연구개발에 자원을 나누고 있는 기업은 향후 시장 기회를 획득하기 위한 전략적 포지셔닝 걸립니다. 게다가 이 기업들은 인구가 많고 인플루엔자의 이환율이 상승하고 있는 신흥 시장에서 확고한 존재를 확립하기 위해 노력하고 있습니다. 또한, 특히 인플루엔자의 유행기에는 조기 항바이러스제물 개입의 장점에 대한 인지를 촉진하기 위해 각 회사가 협력하여 노력하고 있습니다.

소개
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아 태평양(APAC)
- 개요
- 아시아 태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
남미
- 개요
- 남미의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제13장 주요 벤더 분석-인플루엔자 치료제 산업

경쟁 대시보드
기업 프로파일
- AstraZeneca plc
- Teva Pharmaceutical Industries Ltd
- BioCryst Pharmaceuticals, Inc.
- Sanofi
- Daiichi Sankyo Company
- Novartis AG
- F. Hoffmann-La Roche AG
- NATCO Pharma Limited
- GlaxoSmithKline plc
- Lupin
- 기타

제14장 애널리스트의 전방위 전망

LYJ

REPORT HIGHLIGHT

Influenza Medications Market size was valued at USD 932.43 million in 2023, expanding at a CAGR of 7.2% from 2024 to 2032.

Medications for influenza are utilized to either treat or prevent infections caused by the flu. Antiviral drugs that target influenza viruses serve as a crucial complement to the influenza vaccine in managing the disease. These antiviral agents function by hindering the replication of the influenza virus, which in turn alleviates the severity and shortens the duration of symptoms. Their efficacy is maximized when administered promptly, preferably within 48 hours of the onset of symptoms. Thus, influenza medications play a vital role in alleviating flu symptoms and mitigating the overall effects of the infection.

Influenza Medications Market- Market Dynamics

The increasing incidence of influenza is expected to drive the growth of the market

Influenza is a recurring illness that manifests seasonally, resulting in annual outbreaks across various regions globally. The heightened occurrence during the flu season leads to an increased demand for pharmaceutical interventions. Additionally, sporadic flu pandemics or epidemics can considerably elevate the incidence of influenza, resulting in surges in the need for antiviral therapies and preventive strategies. The Centers for Disease Control and Prevention (CDC) estimates that this season has witnessed at least 35 million cases, 400,000 hospitalizations, and 25,000 fatalities attributed to the flu. Moreover, advancements in the development of antiviral medications and integrated treatment methodologies present significant growth opportunities for the market. Nonetheless, the high costs associated with novel medications may pose challenges to market expansion.

Influenza Medications Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.2% over the forecast period (2024-2032)

Based on Drug Type segmentation, Antiviral drugs were predicted to show maximum market share in the year 2023

Based on Influenza Type segmentation, Influenza A was the leading type in 2023

Based on Age Group segmentation, Adults were the leading type in 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

Based on Distribution Channel segmentation, Hospital pharmacies were the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Influenza Medications Market- Segmentation Analysis:

The Global Influenza Medications Market is segmented based on Drug Type, Influenza Type, Age Group, Route of Administration, Distribution Channel, and Region.

The market is segmented into three classifications according to Drug Type: Antiviral drugs, Antihistamines, and Analgesics and Antipyretics. Antiviral drugs hold a dominant position in the market. These drugs are formulated to alleviate the intensity and length of flu symptoms, and in certain instances, they may also avert complications.

The market is classified into two segments according to the influenza type: Influenza A and Influenza B. Influenza A holds a predominant position in the market. It is recognized for its role in triggering yearly flu epidemics and possesses the capacity to result in pandemics owing to its rapid mutation capabilities.

The market is classified into three segments according to age groups: Adults, Pediatric, and Geriatric. The Adult segment dominates the market. The Influenza Medications Market focused on adults represents a crucial segment, given that adults frequently experience seasonal influenza, with the severity of the illness influenced by factors such as age, underlying health conditions, and vaccination history.

The market is segmented into three categories according to the route of administration: Oral, Inhaled, and Intravenous. The Oral category holds a dominant position in the market. Oral antiviral medications are frequently the primary option for combating influenza, especially in the treatment of mild to moderate cases.

The market is segmented into three distinct categories according to the Distribution Channel: Hospital pharmacies, Retail pharmacies, and online pharmacies. Hospital pharmacies dominate the market. Hospitals necessitate efficient antiviral treatments to care for patients who are at an increased risk of severe outcomes, including the elderly, individuals with pre-existing health conditions, and those with compromised immune systems.

Influenza Medications Market- Geographical Insights

This market is geographically extensive, encompassing North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These areas are further categorized based on the countries contributing to business activities. North America leads the market, driven by an increase in the adoption of advanced drug therapies and a rise in healthcare spending. The regulatory framework in North America, especially in the United States, facilitates the expedited approval and implementation of new influenza treatments. This includes access to innovative therapies that may not yet be accessible in other regions. In 2022, a total of 37 new drugs, referred to as novel drugs, were approved for the first time in the U.S. Additionally, previously approved drugs were authorized for new applications, including new indications and patient demographics, as reported by the National Center for Health Statistics. Europe positions as the second largest region for market expansion, attributed to increasing awareness and early diagnosis.

Influenza Medications Market- Competitive Landscape:

The Influenza Medications Market exhibits a high level of competitiveness, characterized by numerous pharmaceutical firms striving to secure a larger share, especially within the antiviral sector. A significant focus of this competition lies in the innovation of new antiviral medications that employ unique mechanisms of action. Firms that allocate resources towards research and development to formulate advanced influenza therapies capable of overcoming resistance and providing enhanced efficacy or convenience are strategically positioning themselves to seize future market opportunities. Additionally, these companies are working to establish a robust presence in emerging markets, where a substantial population and a rising incidence of influenza present considerable sales potential. There is also a concerted effort among companies to promote awareness regarding the advantages of early antiviral intervention, particularly during the flu season.

Recent Developments:

In May 2024, AstraZeneca is set to present new clinical and real-world findings from its prominent inhaled, biologic, and early-stage respiratory portfolio at the American Thoracic Society (ATS) International Conference, taking place in San Diego, CA, from May 17 to May 22, 2024. The company will unveil 59 abstracts, which include 12 late-breaking posters, concentrating on the unmet needs associated with chronic obstructive pulmonary disease (COPD), severe asthma, and eosinophilic granulomatosis with polyangiitis (EGPA), along with other chronic respiratory conditions.

In October 2023, Sanofi and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. announced a partnership aimed at the co-development and co-commercialization of the asset TEV'574. This asset is presently undergoing Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, both of which are forms of inflammatory bowel disease.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INFLUENZA MEDICATIONS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

AstraZeneca plc
Teva Pharmaceutical Industries Ltd
BioCryst Pharmaceuticals, Inc.
Sanofi
Daiichi Sankyo Company
Novartis AG
F. Hoffmann-La Roche AG
NATCO Pharma Limited
GlaxoSmithKline plc
Lupin
Others

GLOBAL INFLUENZA MEDICATIONS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

Antiviral Drugs
Single Antiviral Drugs
Combination Antiviral Drugs
Antihistamines
Analgesics
Antipyretics

GLOBAL INFLUENZA MEDICATIONS MARKET, BY INFLUENZA TYPE- MARKET ANALYSIS, 2019 - 2032

Influenza A
Influenza B

GLOBAL INFLUENZA MEDICATIONS MARKET, BY AGE GROUP- MARKET ANALYSIS, 2019 - 2032

Adults
Pediatric
Geriatric

GLOBAL INFLUENZA MEDICATIONS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Inhaled
Intravenous

GLOBAL INFLUENZA MEDICATIONS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

GLOBAL INFLUENZA MEDICATIONS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Influenza Medications Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Influenza Medications Market Snippet by Drug Type
- 2.1.2. Influenza Medications Market Snippet by Influenza Type
- 2.1.3. Influenza Medications Market Snippet by Age Group
- 2.1.4. Influenza Medications Market Snippet by Route of Administration
- 2.1.5. Influenza Medications Market Snippet by Distribution Channel
- 2.1.6. Influenza Medications Market Snippet by Country
- 2.1.7. Influenza Medications Market Snippet by Region
2.2. Competitive Insights

3. Influenza Medications Key Market Trends

3.1. Influenza Medications Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Influenza Medications Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Influenza Medications Market Opportunities
3.4. Influenza Medications Market Future Trends

4. Influenza Medications Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Influenza Medications Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Influenza Medications Market Landscape

6.1. Influenza Medications Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Influenza Medications Market - By Drug Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
- 7.1.2. Antiviral Drugs
  - 7.1.2.1. Single Antiviral Drugs
  - 7.1.2.2. Combination Antiviral Drugs
- 7.1.3. Antihistamines
- 7.1.4. Analgesics
- 7.1.5. Antipyretics

8. Influenza Medications Market - By Influenza Type

8.1. Overview
- 8.1.1. Segment Share Analysis, By Influenza Type, 2023 & 2032 (%)
- 8.1.2. Influenza A
- 8.1.3. Influenza B

9. Influenza Medications Market - By Age Group

9.1. Overview
- 9.1.1. Segment Share Analysis, By Age Group, 2023 & 2032 (%)
- 9.1.2. Adults
- 9.1.3. Pediatric
- 9.1.4. Geriatric

10. Influenza Medications Market - By Route of Administration

10.1. Overview
- 10.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
- 10.1.2. Oral
- 10.1.3. Inhaled
- 10.1.4. Intravenous

11. Influenza Medications Market - By Distribution Channel

11.1. Overview
- 11.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
- 11.1.2. Hospital Pharmacies
- 11.1.3. Retail Pharmacies
- 11.1.4. Online Pharmacies

12. Influenza Medications Market- By Geography

12.1. Introduction
- 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
12.2. North America
- 12.2.1. Overview
- 12.2.2. Influenza Medications Key Manufacturers in North America
- 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.2.5. North America Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
- 12.2.6. North America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
- 12.2.7. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.2.8. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.2.9. U.S.
  - 12.2.9.1. Overview
  - 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.2.9.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.2.9.4. U.S. Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.2.9.5. U.S. Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.2.9.6. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.2.10. Canada
  - 12.2.10.1. Overview
  - 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.2.10.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.2.10.4. Canada Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.2.10.5. Canada Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.2.10.6. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3. Europe
- 12.3.1. Overview
- 12.3.2. Influenza Medications Key Manufacturers in Europe
- 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.3.5. Europe Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
- 12.3.6. Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
- 12.3.7. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.9. Germany
  - 12.3.9.1. Overview
  - 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.9.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.9.4. Germany Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.3.9.5. Germany Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.3.9.6. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.10. Italy
  - 12.3.10.1. Overview
  - 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.10.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.10.4. Italy Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.3.10.5. Italy Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.3.10.6. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.10.7. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.11. United Kingdom
  - 12.3.11.1. Overview
  - 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.11.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.11.4. United Kingdom Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.3.11.5. United Kingdom Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.3.11.6. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.11.7. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.12. France
  - 12.3.12.1. Overview
  - 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.12.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.12.4. France Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.3.12.5. France Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.3.12.6. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.12.7. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.13. Russia
  - 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.13.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.13.3. Russia Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.3.13.4. Russia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.3.13.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.13.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.14. Netherlands
  - 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.14.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.14.3. Netherlands Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.3.14.4. Netherlands Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.3.14.5. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.14.6. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.15. Sweden
  - 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.15.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.15.3. Sweden Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.3.15.4. Sweden Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.3.15.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.16. Poland
  - 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.16.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.16.3. Poland Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.3.16.4. Poland Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.17. Rest of Europe
  - 12.3.17.1. Overview
  - 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.17.4. Rest of the Europe Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.3.17.5. Rest of the Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.3.17.6. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.17.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
- 12.4.1. Overview
- 12.4.2. Influenza Medications Key Manufacturers in Asia Pacific
- 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.4.5. Asia Pacific Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
- 12.4.6. Asia Pacific Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
- 12.4.7. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.8. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.9. India
  - 12.4.9.1. Overview
  - 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.9.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.9.4. India Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.4.9.5. India Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.4.9.6. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.9.7. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.10. China
  - 12.4.10.1. Overview
  - 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.10.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.10.4. China Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.4.10.5. China Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.4.10.6. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.10.7. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.11. Japan
  - 12.4.11.1. Overview
  - 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.11.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.11.4. Japan Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.4.11.5. Japan Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.4.11.6. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.12. South Korea
  - 12.4.12.1. Overview
  - 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.12.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.12.4. South Korea Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.4.12.5. South Korea Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.4.12.6. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.13. Australia
  - 12.4.13.1. Overview
  - 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.13.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.13.4. Australia Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.4.13.5. Australia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.4.13.6. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.14. Thailand
  - 12.4.14.1. Overview
  - 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.14.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.14.4. Thailand Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.4.14.5. Thailand Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.4.14.6. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.14.7. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.15. Indonesia
  - 12.4.15.1. Overview
  - 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.15.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.15.4. Indonesia Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.4.15.5. Indonesia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.4.15.6. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.15.7. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.16. Philippines
  - 12.4.16.1. Overview
  - 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.16.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.16.4. Philippines Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.4.16.5. Philippines Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.4.16.6. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.17. Rest of APAC
  - 12.4.17.1. Overview
  - 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.17.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.17.4. Rest of APAC Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.4.17.5. Rest of APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.4.17.6. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.17.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.5. Latin America
- 12.5.1. Overview
- 12.5.2. Influenza Medications Key Manufacturers in Latin America
- 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.5.5. Latin America Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
- 12.5.6. Latin America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
- 12.5.7. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.8. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.9. Brazil
  - 12.5.9.1. Overview
  - 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.9.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.5.9.4. Brazil Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.5.9.5. Brazil Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.5.9.6. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.10. Mexico
  - 12.5.10.1. Overview
  - 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.10.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.5.10.4. Mexico Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.5.10.5. Mexico Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.5.10.6. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.11. Argentina
  - 12.5.11.1. Overview
  - 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.11.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.5.11.4. Argentina Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.5.11.5. Argentina Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.5.11.6. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.12. Colombia
  - 12.5.12.1. Overview
  - 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.12.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.5.12.4. Colombia Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.5.12.5. Colombia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.5.12.6. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.13. Rest of LATAM
  - 12.5.13.1. Overview
  - 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.5.13.4. Rest of LATAM Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.5.13.5. Rest of LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.5.13.6. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
- 12.6.1. Overview
- 12.6.2. Influenza Medications Key Manufacturers in Middle East and Africa
- 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.6.5. Middle East and Africa Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
- 12.6.6. Middle East and Africa Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
- 12.6.7. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.9. Saudi Arabia
  - 12.6.9.1. Overview
  - 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.9.4. Saudi Arabia Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.6.9.5. Saudi Arabia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.6.9.6. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.10. United Arab Emirates
  - 12.6.10.1. Overview
  - 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.10.4. United Arab Emirates Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.6.10.5. United Arab Emirates Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.6.10.6. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.11. Israel
  - 12.6.11.1. Overview
  - 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.11.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.11.4. Israel Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.6.11.5. Israel Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.6.11.6. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.12. Turkey
  - 12.6.12.1. Overview
  - 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.12.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.12.4. Turkey Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.6.12.5. Turkey Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.6.12.6. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.13. Algeria
  - 12.6.13.1. Overview
  - 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.13.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.13.4. Algeria Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.6.13.5. Algeria Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.6.13.6. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.14. Egypt
  - 12.6.14.1. Overview
  - 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.14.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.14.4. Egypt Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.6.14.5. Egypt Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.6.14.6. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.15. Rest of MEA
  - 12.6.15.1. Overview
  - 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.15.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.15.4. Rest of MEA Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
  - 12.6.15.5. Rest of MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 12.6.15.6. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.15.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Influenza Medications Industry

13.1. Competitive Dashboard
13.2. Company Profiles
- 13.2.1. AstraZeneca plc
- 13.2.2. Teva Pharmaceutical Industries Ltd
- 13.2.3. BioCryst Pharmaceuticals, Inc.
- 13.2.4. Sanofi
- 13.2.5. Daiichi Sankyo Company
- 13.2.6. Novartis AG
- 13.2.7. F. Hoffmann-La Roche AG
- 13.2.8. NATCO Pharma Limited
- 13.2.9. GlaxoSmithKline plc
- 13.2.10. Lupin
- 13.2.11. Others

14. 360 Degree Analyst View

15. Appendix

15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us